M. Ahmadian, J. M. Suh, N. Hah, C. Liddle, A. R. Atkins et al., PPARgamma signaling and metabolism: the good, the bad and the future, Nat. Med, vol.19, pp.557-566, 2013.

J. M. Allan and L. B. Travis, Mechanisms of therapy-related carcinogenesis, Nat. Rev. Cancer, vol.5, pp.943-955, 2005.

T. Andrew, P. Y. Glenn, M. Marshall, and L. Tao, Neuroblastoma: a malignancy due to cell differentiation block, pp.79-84, 2012.

C. J. Bachurski, N. G. Theodorakis, R. M. Coulson, C. , and D. W. , An amino-terminal tetrapeptide specifies cotranslational degradation of beta-tubulin but not alpha-tubulin mRNAs, Mol. Cell. Biol, vol.14, pp.4076-4086, 1994.

M. Benkoussa, C. Brand, M. H. Delmotte, P. Formstecher, and P. Lefebvre, Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter, Mol. Cell. Biol, vol.22, pp.4522-4534, 2002.

A. Bonni, D. D. Ginty, H. Dudek, and M. E. Greenberg, Serine 133-phosphorylated CREB induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals, Mol. Cell. Neurosci, vol.6, pp.168-183, 1995.

G. M. Brodeur and R. Bagatell, Mechanisms of neuroblastoma regression, Nat. Rev. Clin. Oncol, vol.11, pp.704-713, 2014.

J. Celay, I. Blanco, P. Lazcoz, M. Rotinen, J. S. Castresana et al., Changes in gene expression profiling of apoptotic genes in neuroblastoma cell lines upon retinoic acid treatment, PLoS ONE, vol.8, p.62771, 2013.

I. Cellai, S. Benvenuti, P. Luciani, A. Galli, E. Ceni et al., Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells, Br. J. Cancer, vol.95, pp.879-888, 2006.

M. C. Chiang, Y. C. Cheng, H. M. Chen, Y. J. Liang, Y. et al., Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway, Mitochondrion, vol.14, pp.7-17, 2014.

S. Chintharlapalli, S. Papineni, M. Konopleva, M. Andreef, I. Samudio et al., 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways, Mol. Pharmacol, vol.68, pp.119-128, 2005.

R. Cotterman and P. S. Knoepfler, N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b, PLoS ONE, vol.4, p.5799, 2009.

D. Giacomo, E. Benedetti, E. Cristiano, L. Antonosante, A. Angelo et al., Roles of PPAR transcription factors in the energetic metabolic switch occurring during adult neurogenesis, Cell Cycle, vol.16, pp.59-72, 2017.

E. Draberova, Z. Lukas, D. Ivanyi, V. Viklicky, and P. Draber, Expression of class III beta-tubulin in normal and neoplastic human tissues, Histochem. Cell Biol, vol.109, pp.231-239, 1998.

A. E. El-kenawi and A. B. El-remessy, Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales, Br. J. Pharmacol, vol.170, pp.712-729, 2013.

R. M. Evans and D. J. Mangelsdorf, Nuclear receptors, RXR, and the Big Bang, Cell, vol.157, pp.255-266, 2014.

Z. Fanti, F. F. De-miguel, and M. E. Martinez-perez, A method for semiautomatic tracing and morphological measuring of neurite outgrowth from DIC sequences, Conf. Proc. IEEE Eng. Med. Biol. Soc, pp.1196-1199, 2008.

B. M. Forman, J. Chen, and R. M. Evans, The peroxisome proliferatoractivated receptors: ligands and activators, Ann. N. Y. Acad. Sci, vol.804, pp.266-275, 1996.

S. Fransson, M. Hansson, K. Ruuth, A. Djos, A. Berbegall et al., Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors, Genes Chromosomes Cancer, vol.54, pp.99-109, 2015.

H. Futami and R. Sakai, All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK, Cancer Lett, vol.297, pp.220-225, 2010.

G. A. Gonzalez and M. R. Montminy, Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133, Cell, vol.59, pp.675-680, 1989.

N. M. Gulaya, G. L. Volkov, V. M. Klimashevsky, N. N. Govseeva, and A. A. Melnik, Changes in lipid composition of neuroblastoma C1300 N18 cell during differentiation, Neuroscience, vol.30, pp.90361-90369, 1989.

G. Han, B. Chang, M. J. Connor, and N. Sidell, Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells, Differentiation, vol.59, pp.61-69, 1995.

S. W. Han, M. E. Greene, J. Pitts, R. K. Wada, and N. Sidell, Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells, Clin. Cancer Res, vol.7, pp.98-104, 2001.

S. Han, R. K. Wada, and N. Sidell, Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferatoractivated receptor gamma, Cancer Res, vol.61, pp.3998-4002, 2001.

R. Hannah, M. Beck, R. Moravec, and T. Riss, Cell Titer-Glo TN luminescent cell viability assay: a sensitive and rapid method for determining cell viability, Cell Notes, vol.2, pp.11-13, 2001.

M. K. Hasan, A. Nafady, A. Takatori, S. Kishida, M. Ohira et al., ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma, Sci. Rep, vol.3, p.3450, 2013.

R. A. Heyman, D. J. Mangelsdorf, J. A. Dyck, R. B. Stein, G. Eichele et al., 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor, Cell, vol.68, pp.397-406, 1992.

T. Honda, G. W. Gribble, N. Suh, H. J. Finlay, B. V. Rounds et al., Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages, J. Med. Chem, vol.43, pp.1866-1877, 2000.

T. Honda, B. V. Rounds, L. Bore, F. G. Favaloro, G. W. Gribble et al., Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages, Bioorg. Med. Chem. Lett, vol.9, pp.3429-3434, 1999.

N. Idres, J. Marill, M. A. Flexor, and G. G. Chabot, Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers, J. Biol. Chem, vol.277, pp.31491-31498, 2002.

T. Ikeda, Y. Nakata, F. Kimura, K. Sato, K. Anderson et al., Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, Mol. Cancer Ther, vol.3, pp.39-45, 2004.

Y. Ito, P. Pandey, M. B. Sporn, R. Datta, S. Kharbanda et al., The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism, Mol. Pharmacol, vol.59, pp.1094-1099, 2001.

J. J. Jimenez and A. A. Yunis, Tumor cell rejection through terminal cell differentiation, Science, vol.238, pp.1278-1280, 1987.

G. S. Jung, K. M. Lee, J. K. Park, S. K. Choi, J. et al., Morphogenetic and neuronal characterization of human neuroblastoma multicellular spheroids cultured under undifferentiated and all-trans-retinoic acid-differentiated conditions, BMB Rep, vol.46, pp.276-281, 2013.

K. M. Jung, K. S. Park, J. H. Oh, S. Y. Jung, K. H. Yang et al., Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-delta12,14-prostaglandin J2, Mol. Pharmacol, vol.63, pp.607-616, 2003.

H. Kawamata, M. Tachibana, T. Fujimori, and Y. Imai, Differentiationinducing therapy for solid tumors, Curr. Pharm. Des, vol.12, pp.379-385, 2006.

S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors, Nature, vol.358, pp.771-774, 1992.

N. E. Kohl, N. Kanda, R. R. Schreck, G. Bruns, S. A. Latt et al., Transposition and amplification of oncogene-related sequences in human neuroblastomas, Cell, vol.35, issue.2, pp.90169-90170, 1983.

S. Koschmieder, F. D'alo, H. Radomska, C. Schoneich, J. S. Chang et al., CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha, Blood, vol.110, pp.3695-3705, 2007.

H. Lapillonne, M. Konopleva, T. Tsao, D. Gold, T. Mcqueen et al., Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells, Cancer Res, vol.63, pp.5926-5939, 2003.

G. Lee, F. Elwood, J. Mcnally, J. Weiszmann, M. Lindstrom et al., T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities, J. Biol. Chem, vol.277, pp.19649-19657, 2002.

J. Li and L. Kretzner, The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N-or c-myc, Mol. Cell. Biochem, vol.250, pp.91-105, 2003.

E. Lopci, Neuroblastoma: from diagnosis to treatment, J. Pediatr. Oncol, vol.3, pp.38-42, 2015.

O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem, vol.193, pp.265-275, 1951.

G. Maresca, M. Natoli, M. Nardella, I. Arisi, D. Trisciuoglio et al., LMNA knock-down affects differentiation and progression of human neuroblastoma cells, PLoS ONE, vol.7, p.45513, 2012.

K. Matsushita, K. Uchida, S. Saigusa, S. Ide, K. Hashimoto et al., Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients, Pediatr. Surg. Int, vol.29, pp.363-368, 2013.

K. K. Matthay, J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris et al., Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N Engl. J. Med, vol.341, pp.1165-1173, 1999.

K. S. Mix, C. I. Coon, E. D. Rosen, N. Suh, M. B. Sporn et al., Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling, Mol. Pharmacol, vol.65, pp.309-318, 2004.

D. D. Mruk and C. Y. Cheng, Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits, Spermatogenesis, vol.1, pp.121-122, 2011.

I. Muller, K. Larsson, A. Frenzel, G. Oliynyk, H. Zirath et al., Targeting of the MYCN protein with small molecule c-MYC inhibitors, PLoS ONE, vol.9, p.97285, 2014.

D. M. Murphy, P. G. Buckley, K. Bryan, S. Das, L. Alcock et al., Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation, PLoS ONE, vol.4, p.8154, 2009.

A. Negroni, S. Scarpa, A. Romeo, S. Ferrari, A. Modesti et al., Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line, Cell Growth Differ, vol.2, pp.511-518, 1991.

L. Passoni, L. Longo, P. Collini, A. M. Coluccia, F. Bozzi et al., Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients, Cancer Res, vol.69, pp.7338-7346, 2009.

S. M. Pemrick, D. A. Lucas, and J. F. Grippo, The retinoid receptors, Leukemia, vol.8, pp.1-10, 1994.

G. B. Pierce, W. , and C. , Differentiation of malignant to benign cells, Cancer Res, vol.31, pp.127-134, 1971.

J. Qiao, P. Paul, S. Lee, L. Qiao, E. Josifi et al., PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation, Biochem. Biophys. Res. Commun, vol.424, pp.421-426, 2012.

A. B. Rothenberg, W. E. Berdon, G. J. D'angio, D. J. Yamashiro, and R. A. Cowles, Neuroblastoma-remembering the three physicians who described it a century ago, Pediatr. Radiol, vol.39, pp.155-160, 2009.

G. Schleiermacher, I. Janoueix-lerosey, and O. Delattre, Recent insights into the biology of neuroblastoma, Int. J. Cancer, vol.135, pp.2249-2261, 2014.

T. D. Schmittgen and K. J. Livak, Analyzing real-time PCR data by the comparative C(T) method, Nat. Protoc, vol.3, pp.1101-1108, 2008.

C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis, Nat. Methods, vol.9, pp.671-675, 2012.

M. Schwab, K. Alitalo, K. H. Klempnauer, H. E. Varmus, J. M. Bishop et al., Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour, Nature, vol.305, pp.245-248, 1983.

L. Schweigerer, S. Breit, A. Wenzel, K. Tsunamoto, R. Ludwig et al., Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity, Cancer Res, vol.50, pp.4411-4416, 1990.

T. Servidei, R. Morosetti, C. Ferlini, G. Cusano, G. Scambia et al., The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines, Oncol. Res, vol.14, pp.345-354, 2004.

J. M. Slack, Essential Developmental Biology, 2012.

G. Speranza, M. E. Gutierrez, S. Kummar, J. M. Strong, R. J. Parker et al., Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors, Cancer Chemother. Pharmacol, vol.69, pp.431-438, 2012.

Y. Tabe, M. Konopleva, Y. Kondo, R. Contractor, T. Tsao et al., PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL, Cancer Biol. Ther, vol.6, 1967.

K. Tanaka, K. Tamiya-koizumi, K. Hagiwara, H. Ito, A. Takagi et al., Role of down-regulated neutral ceramidase during all-trans retinoic acid-induced neuronal differentiation in SH-SY5Y neuroblastoma cells, J. Biochem, vol.151, pp.611-620, 2012.

J. J. Tumilowicz, W. W. Nichols, J. J. Cholon, and A. E. Greene, Definition of a continuous human cell line derived from neuroblastoma, Cancer Res, vol.30, pp.2110-2118, 1970.

U. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro, Toxicology, vol.213, pp.157-168, 2005.

N. V. Varlakhanova, R. F. Cotterman, W. N. Devries, J. Morgan, L. R. Donahue et al., myc maintains embryonic stem cell pluripotency and self-renewal, Differentiation, vol.80, pp.9-19, 2010.

R. P. Warrell, S. R. Frankel, W. H. Miller, D. A. Scheinberg, L. M. Itri et al., Differentiation therapy of acute promyelocytic Leukemia with tretinoin (all-trans-retinoic Acid), N. Engl. J. Med, vol.324, pp.1385-1393, 1991.

P. Y. Wu, Y. F. Liao, H. F. Juan, H. C. Huang, B. J. Wang et al., Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma, PLoS ONE, vol.9, p.88795, 2014.

J. Xing, D. D. Ginty, and M. E. Greenberg, Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase, Science, vol.273, pp.959-963, 1996.

T. J. Yen, P. S. Machlin, C. , and D. W. , Autoregulated instability of beta-tubulin mRNAs by recognition of the nascent amino terminus of beta-tubulin, Nature, vol.334, pp.580-585, 1988.

M. M. Yore, A. N. Kettenbach, M. B. Sporn, S. A. Gerber, and K. T. Liby, Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR, PLoS ONE, vol.6, 2011.

A. L. Yu, A. L. Gilman, M. F. Ozkaynak, W. B. London, S. G. Kreissman et al., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma, N. Engl. J. Med, vol.363, pp.1324-1334, 2010.

C. Zhang, X. Ni, M. Konopleva, M. Andreeff, and M. Duvic, The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sezary syndrome cells, J. Invest. Dermatol, vol.123, pp.380-387, 2004.

J. Zhou, Advances and prospects in cancer immunotherapy, New J. Sci, p.13, 2014.

H. Zirath, A. Frenzel, G. Oliynyk, L. Segerstrom, U. K. Westermark et al., MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells, Proc. Natl. Acad. Sci. U.S.A, vol.110, pp.10258-10263, 2013.